A carregar...

Denosumab in Postmenopausal Osteoporosis: What the Clinician Needs to Know

Denosumab is a subcutaneously (SC) administered investigational fully human monoclonal antibody to receptor activator of nuclear factor-kB ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the principal mediator of osteoclastic bone resorption. RANKL stimulates the format...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Autor principal: Lewiecki, E. Michael
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2009
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3382669/
https://ncbi.nlm.nih.gov/pubmed/22870424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X09343221
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!